Palopegteriparatide Benefits Sustained in Adults With Chronic Hypoparathyroidism

(MedPage Today) -- ORLANDO -- Palopegteriparatide (Yorvipath) led to sustained improvements over 2 years in adults with chronic hypoparathyroidism, according to long-term phase III PaTHway trial results.
By week 104, nearly all participants...